CDK4/6 inhibitors in breast cancer: spotting the difference,Nature Medicine

当前位置： X-MOL 学术 › Nat. Med. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

CDK4/6 inhibitors in breast cancer: spotting the difference
Nature Medicine ( IF 82.9 ) Pub Date : 2021-11-08 , DOI: 10.1038/s41591-021-01570-9
Jose Manuel Perez-Garcia _{1,

2,

3} , Javier Cortes _{1,

2,

3,

4,

5} , Antonio Llombart-Cussac _{2,

3,

6}

Affiliation

A phase 3 study with dalpiciclib reinforces the efficacy of CDK4/6 inhibitors in select patients with metastatic breast cancer; with several such inhibitors available, more evidence is needed to help guide treatment decisions.

中文翻译：